Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06381180 · ClinicalTrials.gov registry record · Phase 1
Warrior CARE: Cannabis Behavioral Health
A Phase 1 study, sponsored by Wayne State University.
- Not yet
- Registry status
- Phase 1
- Development phase
- 500
- Enrollment target
NCT06381180: Clinical Trial Phase 1 study, sponsored by Wayne State University.
NCT06381180 is a Phase 1 study that has not yet begun recruiting, run by Wayne State University. The registered enrollment target is 500 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (733% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06381180, a Phase 1 study, has not yet begun recruiting, sponsored by Wayne State University.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 500 participants
- Enrollment target
Study Summary
This study is a randomized, controlled clinical trial to examine the therapeutic potential of cannabinoids for treating veterans with PTSD and suicidal ideation.
Primary Outcome
PTSD diagnosis will be assessed using the Clinician-Administered PTSD Scale (CAPS-5) for DSM-5 Total Severity Score, a well-validated, semi-structured clinician interview that determines the presence and severity of PTSD symptoms and diagnosis consistent with the DSM-5 and allows for assessing changes in symptom severity over time.
Interventions
- DRUG Placebo
- DRUG Cannabidiol
- DRUG Tetrahydrocannabinol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2025-09-22 |
| Est. Completion | 2030-12-31 |
| Phase | Phase 1 |
What is known before NCT06381180 opens enrollment
NCT06381180 is an interventional study that assigns participants to a tested intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (733% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT06381180 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06381180 about?
NCT06381180 is a clinical study titled "Warrior CARE: Cannabis Behavioral Health". This study is a randomized, controlled clinical trial to examine the therapeutic potential of cannabinoids for treating veterans with PTSD and suicidal ideation.
What is the current status of trial NCT06381180?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 500 participants. The study started on 2025-09-22. Estimated completion is 2030-12-31.
What interventions are being tested in trial NCT06381180?
The interventions under investigation include: Placebo (DRUG), Cannabidiol (DRUG), Tetrahydrocannabinol (DRUG).
Who is sponsoring clinical trial NCT06381180?
This trial is sponsored by Wayne State University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06381180's enrollment target sits among peer trials
500 44th of 2000 higher than 1,955 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI